End Stage Renal Disease (ESRD) Drug Market Growth Patterns And Forecast Outlook Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The End Stage Renal Disease (ESRD) Drug Market Over The 2026–2030 Period?
The end stage renal disease (esrd) drug market has witnessed rapid growth in recent years. This market is set to expand from $148.55 billion in 2025 to $171.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The historical increase can be ascribed to the rising prevalence of ckd, enhanced awareness of esrd, an increase in dialysis centers, advancements in renal therapeutics, and various government healthcare initiatives.
The end stage renal disease (esrd) drug market size is anticipated to experience significant expansion in the coming years. It is projected to reach $304.07 billion by 2030, growing at a compound annual growth rate (CAGR) of 15.5%. This projected growth is driven by the advancement of precision medicine, the broader availability of homecare dialysis, the integration of AI in patient monitoring, increasing investments in esrd research and development, and the escalating adoption of combination therapies. Key trends in the forecast period involve personalized esrd drug therapy, home-based dialysis solutions, telemedicine integration within chronic kidney disease management, sophisticated drug formulations for secondary complications, and a rising uptake of combination therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Which Factors Are Influencing The Growth Of The End Stage Renal Disease (ESRD) Drug Market?
The increasing incidence of obesity and diabetes is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market moving ahead. Obesity refers to an unhealthy accumulation of abnormal or excessive body fat. Conversely, diabetes is a long-term illness characterized by the pancreas’s inability to produce sufficient insulin or the body’s ineffective use of the insulin it does produce. For individuals suffering from renal disease, effective management of fluid and electrolyte balances, blood pressure, and the removal of waste products via dialysis can enhance overall health, potentially resulting in decreased weight and better regulation of blood sugar. Illustratively, in 2023, the World Obesity Federation projected that by 2035, the economic cost of overweight and obesity would amount to US$ 4.32 trillion annually, representing nearly 3% of global economic activity. Furthermore, in June 2024, the UK’s National Health Service disclosed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not severe enough to be classified as diabetes) in 2023, which was an 18% increase from 3,065,825 cases in 2022. Consequently, the growing prevalence of obesity and diabetes is poised to stimulate demand in the end-stage renal disease (ESRD) drug market.
How Is The End Stage Renal Disease (ESRD) Drug Market Segmented Across Different Segment Categories?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Which Trends Are Shaping The End Stage Renal Disease (ESRD) Drug Market?
Leading firms active within the end-stage renal disease (ESRD) drug market are concentrating on securing product approvals, specifically for medications like Jardiance, to boost their market revenues. Empagliflozin serves as a medication designed to assist individuals with type 2 diabetes and to mitigate the risk of cardiovascular complications in those with type 2 diabetes also experiencing heart failure or cardiovascular disease. As an illustration, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., an American pharmaceutical firm, obtained FDA approval for Jardiance. Jardiance has gained approval for multiple applications, including reducing the likelihood of end-stage kidney disease, cardiovascular mortality, and hospitalization among adults with chronic kidney disease facing progression risk, alongside decreasing the chance of a continuous reduction in estimated glomerular filtration rate (eGFR) for adults with heart failure. This medication, Jardiance, functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and its use is not recommended for patients diagnosed with type 1 diabetes or for those whose eGFR is below 20 ml/min/1.73 m.
Which Organizations Play A Role In The End Stage Renal Disease (ESRD) Drug Market Landscape?
Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Get The Full End Stage Renal Disease (ESRD) Drug Market Report:
Which Region Accounts For The Largest Portion Of The End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized End Stage Renal Disease (ESRD) Drug Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2026, By The Business Research Company
End Stage Renal Disease Esrd Drug Market Report 2026
Late Stage Chronic Kidney Disease Drugs Market Report 2026
Kidney Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
